News Agency
Men's Weekly

Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection

  • Written by PR Newswire

SHANGHAI, June 27, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection (R&D code: 8MW0511). Under the terms of the agreement, Mabwell will grant Qilu...

Read more: Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for...

How Headless CMS Enhances Responsive Design and Layout Flexibility

Image by freepik As digital technology continues to evolve at a breakneck pace, users expect much more from content than ever before, and responsive design is crucial to ensure content not only looks but operates across all screens. No longer are... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion